P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis," published in the November 2024 issue of Gastroenterology by Hu et al. Since 2015, CT-P13, a ...

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than ...

Microbiotica, a clinical-stage biopharma company, has announced the dosing of the first patient in its Phase 1b First-in-Human trial, COMPOSER-1, for MB310 in ulcerative colitis ( ...

INDIGO is the largest clinical trial conducted in patients living with IgG4-RD--Topline INDIGO results expected by the end of 2025-WALTHAM, ...

and by the Belgian Inflammatory Bowel Disease Research and Development Grant 2023. JS and TV are supported by a senior ...

The biomarker assay can be used potentially to enrich clinical trials and monitor patients' disease activity and treatment response.

A randomized controlled trial finds no clear benefit of adding bezlotoxumab to FMT in patients with IBD and recurrent C difficile infection.

Aeglea Biotherapeutics Inc. ( (SYRE) ) has released its Q3 earnings. Here is a breakdown of the information Aeglea Biotherapeutics Inc.

Alcohol can worsen Crohn’s disease symptoms, but the impact varies from person to person. It may depend on what and how much ...

Researchers used pharmacovigilance data to examine the onset of gastrointestinal adverse events associated with the use of biologic therapies for psoriasis.

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the treatment process.